絞り込み

16641

広告

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

著者 Solomon SD , Lindsley K , Vedula SS , Krzystolik MG , Hawkins BS
Cochrane Database Syst Rev.2014 Aug 29 ; 8():CD005139.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (907view , 0users)

Full Text Sources

Medical

Miscellaneous

Age-related macular degeneration (AMD) is the most common cause of uncorrectable severe vision loss in people aged 55 years and older in the developed world. Choroidal neovascularization (CNV) secondary to neovascular AMD accounts for most AMD-related severe vision loss. Anti-vascular endothelial growth factor (anti-VEGF) agents, injected intravitreally, aim to block the growth of abnormal blood vessels in the eye to prevent vision loss and, in some instances, improve vision.
PMID: 25170575 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード